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Abstract: Background and objective: Changes in cannabis legalization regimes in several countries have
influenced the diversification of cannabis use. There is an ever-increasing number of cannabis forms
available, which are gaining popularity for both recreational and therapeutic use. From a therapeutic
perspective, oral cannabis containing ∆-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) is a
promising route of administration but there is still little information about its pharmacokinetics (PK)
effects in humans. The purpose of this systematic review is to provide a general overview of the
available PK data on cannabis and THC after oral administration. Materials and Methods: A search
of the published literature was conducted using the PubMed database to collect available articles
describing the PK data of THC after oral administration in humans. Results: The literature search
yielded 363 results, 26 of which met our inclusion criteria. The PK of oral THC has been studied
using capsules (including oil content), tablets, baked goods (brownies and cookies), and oil and tea
(decoctions). Capsules and tablets, which mainly correspond to pharmaceutical forms, were found
to be the oral formulations most commonly studied. Overall, the results reflect the high variability
in the THC absorption of oral formulations, with delayed peak plasma concentrations compared to
other routes of administration. Conclusions: Oral THC has a highly variable PK profile that differs
between formulations, with seemingly higher variability in baked goods and oil forms. Overall,
there is limited information available in this field. Therefore, further investigations are required to
unravel the unpredictability of oral THC administration to increase the effectiveness and safety of
oral formulations in medicinal use.
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1. Introduction
1.1. Cannabinoids
Cannabis is the most widely used illicit drug worldwide, only surpassed by alcohol and tobacco
when also considering legal substances. Recent investigations have highlighted the therapeutic
potential of cannabis, resulting in a resurgence of its consumption for medical purposes. Although
cannabis continues to be used mostly for recreational purposes, people increasingly consume it to
benefit from its therapeutic properties [1–3].
∆-9-Tetrahydrocannabinol (THC) is the principal source of the psychoactive effects associated with
cannabis use [3]. These effects result from the activity of THC as a partial agonist of the cannabinoid
receptor CB1, which is primarily located in the central nervous system, and CB2, which is predominantly
expressed in the peripheral tissues [4]. THC has observable effects on behavior, nociception, and
appetite, as well as anti-inflammatory, antitumor, and antiemetic properties. THC is also responsible
for the psychotropic effects and addictive and reinforcing properties of cannabis [5].
The other predominant component in the cannabis plant is cannabidiol (CBD), which is the
primary cannabinoid in fiber-type hemps. Unlike THC, CBD does not have a direct effect on the
receptors (CB1 and CB2) responsible for cannabis’ psychoactive effects [6–8], although recent evidence
has demonstrated the negative allosteric activity of CBD on CB1 [9].
CBD is believed to attenuate THC’s psychotropic effects, thereby enhancing the safety (or safety
profile) of cannabis products containing both cannabinoids. However, this interaction is not fully
understood. Previous studies found that CBD does not alter THC’s subjective effects [10–12], but a recent
study reported an increase in plasma THC concentration and a slight exacerbation of THC-induced
impairment in the presence of CBD [13].
Other cannabinoids may play a role in the overall effects of cannabis, such as
∆-8-tetrahydrocannabinol, cannabinol (CBN), cannabicyclol (CBL), cannabichromene (CBC),
and cannabigerol (CBG). However, these cannabinoids have fewer psychotropic effects than THC [14].
1.2. Therapeutic Uses of Cannabis
Cannabinoids exert most of their biological effects through interactions with the endocannabinoid
system. Their wide range of effects makes cannabinoids good candidates for treating many ailments,
including nausea, loss of appetite, neuropathic pain spasticity, epilepsy, chronic pain, etc. [5]. However,
cannabinoids are currently typically prescribed as adjuvant treatments or after a patient does not
respond well to first-line treatments.
The number of countries that have legalized therapeutic cannabis use (medical cannabis) has
grown in recent years. In the Netherlands, the drastic increase in the prevalence of medical cannabis
prescriptions can be explained by the emergence of new formulations, especially cannabis oils [15],
which have become the preferred option for therapeutic use [16].
When considering the purpose of consumption, for medical cannabis users, edible cannabis is one
of the most common consumption modes, along with vaporization [17–19], contrary to recreational
users, who are more likely to smoke or vaporize [18].
1.3. Oral Cannabis and THC and Other Routes of Administration
Recreational cannabis is mainly consumed by smoking, which involves combusting the
herbal cannabis present in a joint, blunt, pipe, bubbler, or bong/water pipe, among other forms.
The psychoactive effects of THC appear in less than a minute after consumption. From the limited
evidence available, it appears that smoking cannabis may be associated with respiratory diseases, as
smoked cannabis contains several toxins and carcinogens also found in tobacco smoke [20]. No country
that has authorized the medical use of cannabis recommends smoking as a method of consumption.
An alternative inhalation-based form that has become popular in recent years is using a vaporizer.
This technique is considered less noxious than regular smoking, as vaporizing does not produce
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the pyrolytic compounds derived from combustion of the dried herb or extract, such as polycyclic
aromatic hydrocarbons. However, vaporizers have been recently associated with acute respiratory
illness, now referred to as e-cigarette or vaping product-use associated lung injury (EVALI) [21,22].
The cause of this condition is currently under investigation, although there is evidence implicating the
vitamin E acetate used as a diluent in vaporizer liquids [23].
Changes in cannabis legalization in several countries have influenced the emergence of a variety
of edible products containing cannabis, which have increasing popularity. At present, edible products
are now available in new formats resembling sugary snacks (hard and soft candies) and baked
goods (brownies, cookies), which appeal especially to young people. From a therapeutic perspective,
oral cannabis intake is promising due to its long-lasting drug effects, easy administration, and reduced
toxicity derived from pyrolytic by-products. To date, the limited information available describes a
slow and erratic absorption, seemingly showing higher bioavailability in oil formulations [24].
1.4. Oral Cannabinoid Preparations
Medical cannabis refers to a broad range of products and preparations that contain cannabis
and cannabinoids for therapeutic purposes. Several medical products with marketing authorization
contain THC as their main component, including dronabinol (synthetic THC), commercialized as
oral capsules (Marinol®) or as an oral solution (Syndros®), and nabilone (a synthetic THC analogue),
which is marketed as oral capsules (Cesamet® or Canemes®). Nabiximols (Sativex®), available as a
buccal spray, also includes CBD in its formulation [14,24–26]. However, few cannabis products have
sufficient evidence to obtain approval for therapeutic use in the USA and several European countries.
Formulations derived from the Cannabis sativa plant that do not have marketing authorization for
medical use are known as “cannabis preparations”. This term encompasses raw cannabis, compound
preparations, and standardized cannabis preparations, which include cannabis flowers, granulates,
and oil extracts [27].
In the Netherlands, cannabis is produced in five standardized strains that are commercially
available and classified by their THC and CBD content [28]. In Italy, the Ministry of Health authorized
the commercialization of standardized cannabis (FM2, 5–8% THC and 7–12% CBD) for medical
purposes, which is produced by the Military Pharmaceutical Institute in Florence [29]. As per
recommendations, this medical cannabis is consumed in decoctions or oils following standardized
indications [30]. In 2018, a new strain of medical cannabis began production (FM1, 13–20% THC and
<1% CBD), but no therapeutic indications are currently authorized for this new strain [31,32]. In Canada,
medical cannabis is manufactured under a public license, mostly in the form of oil. Cannimed® can be
purchased as oil capsules, oil, dried flowers, or in a topical form, allowing oral, vaporized, or topical
administration [33,34].
Edible cannabis is associated with a high rate of emergency department visits, mainly due to
gastrointestinal symptoms, intoxication, and psychiatric effects [35]. The high variability of oral THC
absorption and the delayed onset of effects can lead to the overconsumption of edible preparations,
especially among naive users.
Considering that cannabinoids are proposed to alleviate a wide range of ailments, the identification
and interpretation of their pharmacokinetics (PK) are essential for their use as pharmaceutical products.
The purpose of this review was to examine the available data on THC PK after the oral administration
of cannabis and THC, as reported in humans.
2. Materials and Methods
This systematic review was performed according to PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) guidelines [36].
Potential studies were systematically searched and identified by one of the authors (L.P.). The study
selection was jointly conducted by two of the authors (L.P. and M.F.). After reading the summary of
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each study, in case of a disagreement, the final decision was reached by consensus. The data were
collected by the author L.P. and reviewed by the other authors (M.F. and A.P.P.).
A search of the published literature was conducted using the PubMed database up to March
2020. The keywords used for the search were “oral cannabis”, “edible cannabis”, “oral THC”,
“pharmacokinetic”, “blood collection”, “dronabinol”, “synthetic THC”, “plasma levels”, and “Cmax”.
To be included, studies had to follow a pharmacokinetic model, include at least the maximum plasma
concentration values (Cmax) and time needed to reach the maximum concentrations (Tmax) as
PK parameters, and examine oral administration, although they could also include other routes of
administration. Single-dose studies were preferred, but multiple-dose studies were included if the
blood was collected at various time points following initial dosing. Only articles whose abstracts met
our selected criteria were selected. Animal studies, articles focusing on routes of administration other
than oral, nabilone (a synthetic cannabinoid), nabiximols, and studies of CBD administration were
excluded from the review. Studies featuring the administration of nabiximols were only included if
their preparations were compared to those of other oral cannabis/THC preparations.
Only articles written in English were selected. All articles were reviewed independently by the
authors to determine their relevance in the framework of the current study.
The following data were collected from the reviewed articles: Design of the study, number of
participants, gender, previous experience with cannabis, route of administration, product containing
THC, dose of THC, basic PK measurements (maximum concentration, or Cmax, and time to achieve
maximum concentrations, or Tmax) in plasma or blood, and pharmacological effects (if measured).
In order to evaluate a relationship between the administered dose and peak concentrations (Cmax),
Spearman correlations were conducted between doses of THC and Cmax values in each formulation
group. A linear regression procedure that allows for the calculation of correlation coefficients was
used. Analyses were performed using GraphPad Prism 5.
3. Results
The literature search yielded a total of 363 results, 26 of which met our inclusion criteria
(Figure 1) [37–62]. These studies are summarized in Tables 1–4. Besides the oral administration route,
cannabis was taken in by other routes in eight of the studies, including sublingual, respiratory/inhaled,
buccal, intravenous, and oropharyngeal routes. THC can be present in various dosage forms, each with
different PK properties, which are crucial to know for a molecule intended for therapeutic applications.
The oral absorption of THC was studied using oil capsules, tablets, baked goods (brownies and cookies),
oils, and decoctions. However, there was no information on other products containing cannabis,
including candies and chocolates.
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Table 1. Summary of studies included in this systematic review reporting the pharmacokinetic parameters of ∆-9-tetrahydrocannabinol (THC) following
capsule administration.
References Study Design Participants Route ofAdministration Formulation Dose
Cmax (ng/mL)
Mean ± SD, Median (Range) Tmax (h) Pharmacological Effects
Wall et al., 1983 [37] OL, NP 6 M, 6 F
Oral Capsules
20 mg THC (men)
Men Men
Effects were not assessed.
THC: 14 ± 9.7 b THC: 2.5
11-OH-THC: 6.6 ± 3.4 b 11-OH-THC: 2.0
15 mg THC (women)
Women Women
THC: 9.4 ± 4.5 b THC: 1.75
11-OH-THC: 5.9 ± 2.8 b 11-OH-THC: 1.75
Intravenous
(infusion pump)
Human serum
albumin
4 mg THC (men)
Men Men
THC: 71 ± 34 b THC: 0.42
11-OH-THC: 3.7 ± 2.3 b 11-OH-THC: 0.5
2.2 mg THC (women)
Women Women
THC: 85 ± 26 b THC: 0.17
11-OH-THC: 3.8 ± 2.8 b 11-OH-THC: 0.33
Haney et al., 2003 [38] R, DB, P, C 7 M
Cannabis smokers
Oral
Capsules
(Marinol®)
30 mg THC29,
Placebo naltrexone
THC: 29.9 ± 9.5 b THC: 4 b Subjective effects
Increase in ratings of Good Drug Effect, High,
and Stimulated. Vital effects Decreased HR.
Worsened psychomotor performance.
THC-COOH: 121.9 ± 43.5 b THC-COOH: 2 b
Oral
Capsules
(Marinol®)
30 mg THC
50 mg naltrexone
THC: 21.2 ± 8.6 b THC: 2 b
THC-COOH: 139.0 ± 36.2 b THC-COOH: 3 b
Naef et al., 2003 [39] R, DB, P, C 6 M, 6 F
Cannabis naïve
Oral
Capsules
(Marinol®)
20 mg THC
THC: 7.2 ± 6.9 b, e THC: 1-2 b, e
Subjective effects
Psychotropic and somatic side-effects were
common but usually mild.
Paint tests
No significant reduction in pain.
11-OH-THC: 19.7 ± 6.9 b, e 11-OH-THC: 2 b, e
11-COOH-THC: 241.4 ± 73. b, e 11-COOH-THC: 2–4 b, e
Oral Capsules
20 mg THC
30 mg morphine HCl
THC: 6.7 ± 7.3 b, e -
11-OH-THC: 7.9 ± 8.3 b, e -
11-COOH-THC: 134.7 ± 65.12 b, e -
Oral Capsules(placebo) 30 mg morphine HCl
Oral Capsules(placebo)
Guy et al., 2004 [40]
R, OL, C
followed by an
NR oral dose
6 M, 6 F
Previous experience of
cannabis use
Oral Capsules
10 mg THC
10 mg CBD
THC: 6.35 ± 3.12 (3.04–4.55) THC: 1.05 ± 0.65 (0.5–2.75)
Effects were not assessed.
CBD: 2.47 ± 2.23 (0.47–7.55) CBD: 1.27 ± 0.84 (0.5–3)
11-OH-THC: 7.87 ± 2.96
(4.79–13.64)
11-OH-THC: 1.36 ± 0.63
(0.75–3)
Sublingual Liquid spray
(Sativex®)
10 mg THC
10 mg CBD
THC: 5.54 ± 3.35 (1.14–12.13) THC: 1.63 ± 0.59 (1–3)
CBD: 2.50 ± 1.83 (0.27–6.55) CBD: 1.63 ± 0.68 (0.75–3)
11-OH-THC: 6.24 ± 2.74
(2.67–10.77)
11-OH-THC: 1.58 ± 0.44
(1–2.75)
Buccal
Liquid spray
(Sativex®)
10 mg THC
10 mg CBD
THC: 6.14 ± 5.37 (0.88–19.78) THC: 2.40 ± 1.08 (1–4.5)
CBD: 3.02 ± 3.15 (0.29–9.91) CBD: 2.78 ± 1.31 (1–4.5)
11-OH-THC: 6.13 ± 2.88
(1.83–11.25) 11-OH-THC: 2.40 ± 1.17 (1–4.5)
Oro-pharyngeal Liquid spray
(Sativex®)
10 mg THC
10 mg CBD
THC: 6.11 ± 4.00 (1.94–15.68) THC: 2.23 ± 1.52 (0.75–5)
CBD: 2.61 ± 1.91 (0.41–6.36) CBD: 2.04 ± 1.13 (0.75–5)
11-OH-THC: 6.45 ± 2.91
(2.95–13.49)
11-OH-THC: 2.40 ± 1.22
(1.25–5)
Menetrey et al.,
2005 [41] See also Table 2 for results on capsules and decoction administration.
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Table 1. Cont.
References Study Design Participants Route ofAdministration Formulation Dose
Cmax (ng/mL)
Mean ± SD, Median (Range) Tmax (h) Pharmacological Effects
Nadulski et al.,
2005 [42]
DB, P, C 24
Oral Capsules
10 mg THC
5.4 mg CBD
THC: 4.05 (1.18–10.27) THC: 0.93 (0.55–2.08)
Effects were not assessed.
CBD: 0.95 (0.30–2.57) CBD: 0.99 (0.5–2)
11-OH-THC: 4.88 (1.83–12.34) 11-OH-THC: 1.67 (0.62–2.17)
THC-COOH:35.46 (19.2–70.6) THC-COOH: 1.92 (1.08–3.83)
Oral Capsules 10 mg THC
THC: 3.20 (0.67–7.99) THC: 1.06 (0.5–3.05)
11-OH-THC: 4.48 (1.12–11.14) 11-OH-THC: 1.5 (0.5–3.17)
THC-COOH: 32.9 (12.03–57.63) THC-COOH: 2.07 (0.62–3.92)
Oral Capsules Placebo
Goodwin et al.,
2006 [43] See also Table 2 for results on capsules and oil administration.
Schwilke et al.,
2009 [44]
NR, OL, NP, MD
6 M Daily smokers (positive in
cannabinoids, smoked within
the previous 24 h)
Oral
Capsules
(Marinol®)
Escalating total daily
doses (40-120 mg) for
7 days
First dose 20 mg THC
After 1st dose (single dose): After 1st dose:
Effects were not assessed.
THC: 12.4 ± 3.4 THC: 2.8 (0.33)
11-OH-THC: 8.2 ± 2.0 11-OH-THC: 2.5 (0.18)
THC-COOH: 75.8 ± 9.4 THC-COOH: 3.3 (0.56)
Karschner et al.,
2011 [45]
R, DB, P, DD 6 M, 3 F
Cannabis smokers
Oral
Capsules
(dronabinol)
5 mg THC
THC: 4.7 ± 0.9, 4.6 (1.4–10.4) THC: 3.2 ± 0.3, 3.1 (1.5–4.5)
Effects were not assessed.
11-OH-THC: 3.0 ± 0.4, 2.6
(1.8–5.9)
11-OH-THC: 3.3 ± 0.4, 3.3
(1.5–5.6)
THC-COOH: 69.3 ± 17.6, 57.1
(15.9–179.7)
THC-COOH: 4.4 ± 0.5, 4.3
(2.7–7.5)
Oral
Capsules
(dronabinol)
15 mg THC
THC: 14.3 ± 2.7, 11.2 (3.3–28.5) THC: 3.4 ± 0.5, 3.4 (1.2–5.5)
11-OH-THC: 11.1 ± 2.0, 9.3
(3.6–19.5)
11-OH-THC: 3.4 ± 0.4, 3.6
(1.0–5.5)
THC-COOH: 133.6 ± 36.3, 102.1
(44.5–409.0)
THC-COOH: 4.9 ± 0.5, 5.5
(2.4–7.5)
Sublingual Spray (Sativex®)
5.4 mg THC
5.0 mg CBD
THC: 5.1 ± 1.0, 5.1 (1.2–9.6) THC: 3.3 ± 0.3, 3.5 (1.2–4.5)
CBD: 1.6 ± 0.4, 1.2 (0.6–3.9) CBD: 3.7 ± 0.5, 3.6 (1.0–5.5)
11-OH-THC: 4.2 ± 0.7, 3.7
(2.1– 7.5)
11-OH-THC: 3.6 ± 0.6, 3.3
(1.0–7.5)
THC-COOH: 108.0 ± 30.5, 79.8
(19.1–281.6)
THC-COOH: 4.4 ± 0.7, 4.5
(1.2–7.5)
Sublingual Spray (Sativex®)
16.2 mg THC
15.0 mg CBD
THC: 15.3 ± 3.4, 14.5 (3.2–38.2) THC: 4.0 ± 0.5, 4.5 (1.2–5.6)
CBD: 6.7 ± 2.0, 3.7 (2.0–20.5) CBD: 4.0 ± 0.5, 4.5 (1.2–5.6)
11-OH-THC: 8.4 ± 1.2, 7.6
(3.8–13.7)
11-OH-THC: 3.9 ± 0.5, 3.7
(1.2–5.6)
THC-COOH: 126.6 ± 25.9, 92.4
(55.9–304.1)
THC-COOH: 4.8 ± 0.3, 5.0
(2.6–5.6)
Karschner et al.,
2012 [46]
NR, OL, NP, MD
10 M
Daily smokers (positive
cannabinoids, smoked within
the previous 24 h)
Oral
Capsules
(Marinol®)
Escalating total daily
doses (40-120 mg) for
7 days
Each dose of 20 mg
THC
After 1st dose (single dose): After 1st dose:
Effects were not assessed.
THC: 8.7 ± 4.8, 6.4 (4.1–17.5) THC: 3.0 ± 0.9, 3.0 (2.0–4.0)
11-OH-THC: 4.0 ± 2.1, 3.4
(1.8–7.8)
11-OH-THC: 2.8 ± 0.9, 3.0
(2.0–5.0)
THC-COOH: 38.4 ± 15.9, 36.6
(19.7–68.7)
THC-COOH: 3.1 ± 1.0, 3.0
(2.0–5.0)
Martin-santos et al.,
2012 [47]
R, DB, P, C
16 M
Previous experience of
cannabis use (less than 15
times in their lifetime)
Oral Capsules 10 mg THC
THC: 0.67 ± 0.66 b
THC-COOH: ≈ 5.6 b, d
11-OH-THC: ≈ 0.73 b, d
THC: 2 h b Subjective effects
Significant changes in PANSS, anxiety
(STAI-S), dysphoria (ARCI), sedation (VAMS,
ARCI), and the level of subjective intoxication
(ASI, ARCI). Vital effects Significant increase in
HR No significant differences in SBP and DBP.
Oral Capsules 600 mg CBD
Oral Capsules(placebo)
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Table 1. Cont.
References Study Design Participants Route ofAdministration Formulation Dose
Cmax (ng/mL)
Mean ± SD, Median (Range) Tmax (h) Pharmacological Effects
Eichler et al., 2012 [48] R, DB, C 9 M
Non smokers
Oral
Capsules
(Marinol®)
20 mg THC
THC: 1.03 ± 1.65, 0.48 e, g THC: 1.06 ± 0.19, 1.0 e
Subjective effects
Mild psychotropic effects, with no significant
differences between treatments.
CBD: 0.00 ± 0.00, 0.0 e, g CBD: NA
11-OH-THC: 0.99 ± 0.63, 0.84 e, g 11-OH-THC: 1.67 ± 0.51, 2.0 e
THC-COOH: 7.13 ± 5.64, 7.61 e, g THC-COOH: 1.78 ± 0.96, 2.0 e
CBN: 0.64 ± 0.72, 0.37 e, g CBN: 1.06 ± 0.57, 1.0 e
Oral
Capsules
(extract from
heated Herba
Cannabis)
17.6 mg THC
27.8 mg CBD
THC: 0.42 ± 0.39, 0.25 e, g THC: 0.78 ± 0.27, 1.0 e
CBD: 0.30 ± 0.21, 0.27 e, g CBD: 0.83 ± 0.51, 0.5 e
11-OH-THC: 0.73 ± 0.69, 0.50 e, g 11-OH-THC: 1.44 ± 0.69, 2.0 e
THC-COOH: 5.81 ± 7.59, 3.46 e, g THC-COOH: 2.89 ± 1.05, 2.0 e
CBN: 0.60 ± 0.36, 0.56 e, g CBN: 0.94 ± 0.45, 1.0 e
Oral
Capsules
(extract from
unheated Herba
Cannabis)
10.4 mg THC
14.8 mg CBD
THC: 1.02 ± 0.78, 0.71 e, g THC: 1.17 ± 0.66, 1.0 e
CBD: 1.24 ± 0.87, 0.96 e, g CBD: 1.17 ± 1.17, 1.0 e
11-OH-THC: 0.57 ± 0.42, 0.50 e, g 11-OH-THC: 1.00 ± 0.42, 1.0 e
THC-COOH: 1.94 ± 1.11, 2.28 e, g THC-COOH: 2.11 ± 0.78, 2.0 e
CBN: 0.54 ± 0.30, 0.58 e, g CBN: 1.00 ± 0.42, 1.0 e
Lile JA et al., 2013 [49] B, P, C
4 M, 3 F
Only 5 completed all doses
Regular cannabis use
Oral
Capsules
(Marinol®)
15 mg THC THC: ≈5
d THC: 3 d
Vital effects
Increase in HR.
SBP decreased after 30 mg dose but increased
after 75 and 90 mg doses.
No changes in DBP.
Decrease in finger temperature.
Psychomotor performance
Worsened psychomotor performance.
11-OH-THC: ≈2-3 d 11-OH-THC: 3 d
Oral
Capsules
(Marinol®)
30 mg THC THC: ≈10 d THC: 3
d
11-OH-THC: ≈5 d 11-OH-THC: 3 d
Oral
Capsules
(Marinol®)
45 mg THC THC: ≈17–18
d THC: 2.5 d
11-OH-THC: ≈8–9 d 11-OH-THC: 2 d
Oral
Capsules
(Marinol®)
60 mg THC THC: ≈45 d THC: 3.5
d
11-OH-THC: ≈11 d 11-OH-THC: 3 d
Oral
Capsules
(Marinol®)
75 mg THC THC: ≈42–43 d THC: 4
d
11-OH-THC: ≈12–13 d 11-OH-THC: 4 d
Oral
Capsules
(Marinol®)
90 mg THC THC: ≈53 d THC: 4 d
11-OH-THC: ≈20 d 11-OH-THC: 4 d
Oral Capsules(placebo)
Parikh et al., 2016 [50] R, OL, C
51 MF
No cannabis use in the
previous 90 days
Oral
Oral solution
(Dronabinol)
4.25 mg THC
THC Replicate 1: 1.81 ± 1.26 THC Replicate 1: 1.50(0.50–4.00)
Effects were not assessed.
THC Replicate 2: 2.08 ± 1.30 THC Replicate 2: 1.00(0.50–3.02)
11-OH-THC Replicate 1:
2.53 ± 1.38
11-OH-THC Replicate 1: 1.50
(0.75–4.00)
11-OH-THC Replicate 2:
3.01 ± 1.56
11-OH-THC Replicate 2: 1.50
(0.50–3.02)
Oral Capsules(Dronabinol) 5 mg THC
THC Replicate 1: 2.20 ± 1.51
THC Replicate 2: 2.61 ± 1.69
11-OH-THC Replicate: 3.28 ±
1.78 11-11-OH-THC Replicate 2:
3.98 ± 2.51
THC Replicate 1: 1.00
(0.50–6.00)
THC Replicate 2: 1.50
(0.50–6.00)
11-OH-THC Replicate 1: 1.60
(0.75–6.00)
11-OH-THC Replicate 2: 1.50
(0.50–6.00)
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Table 1. Cont.
References Study Design Participants Route ofAdministration Formulation Dose
Cmax (ng/mL)
Mean ± SD, Median (Range) Tmax (h) Pharmacological Effects
Cherniakov et al.,
2017 [51]
OL, C
9 M
Not exposed within the
previous 4 weeks
Sublingual Spray (Sativex®)
10.8 mg THC
10.0 mg CBD
THC: 1.8 ± 0.2 THC: 2 (1–4)
Effects were not assessed.
CBD: 0.5 ± 0.1 CBD: 3 (1–5)
Oral
THC-CBD-piperine
-PNL capsule
10.8 mg THC
10.0 mg CBD
THC: 5.4 ± 0.01 THC: 1 (1–1.5)
CBD: 2.1 ± 0.4 CBD: 1 (0.5–1.5)
Abbreviations: Cmax, maximum concentration after administration; SD, standard deviations; R, randomized; NR, not-randomized; OL, open label; DB, double-blind; B, blind; P,
placebo-controlled; NP, not placebo-controlled; C, crossover; DD, double-dummy; MD, multiple dose; M, male; F, female; THC, ∆-9 tetrahydrocannabinol; THCA, ∆-9-tetrahydrocannabinolic
acid A; CBD, cannabidiol; CBDA, cannabidiolic acid; 11-OH-THC, 11-hydroxy-THC; THC-COOH, 11-nor-9-carboxy-THC; THC-COOH-gluc, THC–COOH–glucuronide; THCV-COOH,
11-nor-9-carboxy-tetrahydrocannabivarin; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; ARCI, Addiction Research Center Inventory; VAS,
visual analogue scales; VAMS, visual analogue mood scale; PANSS, Positive And Negative Symptom Scale; STAI, State-Trait Anxiety Inventory; ASI, Addiction Severity Index. a Range
corresponds to the range of Cmax. b The maximum value of the time-course of plasma THC. c, the median instead of mean. d, data deduced from a figure. e, the original values for values
presented as the standard error or coefficient of variation of the mean have been transformed in the table to standard deviation. f, the mean values have been calculated from the values
reported in the article. g, values converted from pmol/mL to ng/mL.
Table 2. Summary of studies included in this systematic review reporting the pharmacokinetic parameters for THC following oil or decoction administration.
References Study Design Participants Route ofAdministration Formulation Dose
Cmax (ng/mL)
Mean ± SD, Median (Range) Tmax (h) Pharmacological Effects
Menetrey et al.,
2005 [41]
R, DB, P, C
8 M
Occasional cannabis smokers
Oral Milk decoction 16.5 mg THC
THC: 3.8 (1.5–8.3) b THC: 1 b
Subjective effects
Prototypical effects of THC with a strong
feeling of highness.
Vital effects
Slight to moderate conjunctival reddening.
Slight to moderate tachycardia
Increase of HR after decoction.
11-OH-THC: 4.7 (2.9–7.0) b 11-OH-THC: 1 b
THC-COOH: 27.8 (14.1–42.4) b THC-COOH: 4 b
Oral Milk decoction 45.7 mg THC
THC: 8.4 (3.9–13.1) b THC: 1 b
11-OH-THC: 12.8 (3.4–24.7) b 11-OH-THC: 2.5 b
THC-COOH: 66.2 (29.0–99) b THC-COOH: 2.5 b
Oral
Capsules
(Marinol®)
20 mg THC
THC: 2.8 (nd–5.6) b THC: 1 b
11-OH-THC: 3.9 (1.4–8.5) b 11-OH-THC: 4 b
THC-COOH: 27.8 (5.4–55.4) b THC-COOH: 5.5 b
Oral Decoction(placebo) 0.8 mg THC
Oral Capsules(placebo)
Goodwin et al.,
2006 [43]
R, DB, P, DD,
MD (5 days)
6
Previous experience of
cannabis use
Oral Hemp oil
0.39 mg THC/day
(tablespoon)
THC: 0 f (0.0–0.0) THC: 0.0 f (0.0–0.0)
Subjective effects
Mild prototypical effects of THC.
Vital effects
No difference in BP, HR, and respiratory rate.
11-OH-THC: 0 f (0.0–0.0) 11-OH-THC: 0.0 f (0.0–0.0)
THC-COOH: 1.1 f (0.0–3.1) THC-COOH: 49.7 f (4.5–121)
Oral
Capsules (hemp
oil)
0.47 mg THC/day
THC: 0.0 f (0.0–0.0) THC: 0.0 f (0.0–0.0)
11-OH-THC: 0.0 f (0.0–0.0) 11-OH-THC: 0.0 f (0.0–0.0)
THC-COOH: 1.4 f (0.0–2.6) THC-COOH: 65.3 f (11.0–107)
Oral
Capsules
(dronabinol)
7.5 mg THC/day
THC: 1.5 f (0.6–3.8) THC: 57.6 f (6.5–107)
11-OH-THC: 1.6 f (0.0–2.6) 11-OH-THC: 85.9 f (1.5–107)
THC-COOH: 19.8 f (10.6–43.0) THC-COOH: 107 f (107–107)
Oral Hemp oil 14,8 mg THC/day
THC: 2.1 f (0.7–6.1) THC: 56.5 f (9–107)
11-OH-THC: 1.7 f (0.0–5.6) 11-OH-THC: 28.6 f (6.5–107)
THC-COOH: 12.7 f (11.0–15.2) THC-COOH: 91.5 f (11.5–121)
Oral Placebo
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Table 2. Cont.
References Study Design Participants Route ofAdministration Formulation Dose
Cmax (ng/mL)
Mean ± SD, Median (Range) Tmax (h) Pharmacological Effects
Pellesi et al., 2018 [52] OL, C
6 M, 7 F
Patients with medication
overuse headaches
Oral Decoction
1.85 ± 1.6 mg THC THC: 1.38 ± 0.75 THC: 1.28 ± 0.51
Subjective effects
Intensity of subjective effects was similar in
both formulations. Increased drowsiness after
cannabis oil administration.
Vital effects
No changes in BP and HR.
2.22 ± 0.66 mg
THCA-A THCA: 48.92 ± 26.34 THCA: 1.22 ± 0.26
1.93 ± 1.17 mg CBD CBD: 4.39 ± 3.01 CBD: 0.56 ± 0.17
8.82 ± 2.02 mg CBDA CBDA: 74.61 ± 25.15 CBDA: 0.83 ± 0.35
Oral Oil
2.2 mg THC THC: 3.29 ± 1.39 THC: 1.28 ± 0.36
2.3 mg THCA-A THCA: 65.36 ± 20.40 THCA: 1.33 ± 0.35
2.4 mg CBD CBD: 3.14 ± 2.58 CBD:1 ± 0.25
4.4 mg CBDA CBDA: 55.03 ± 29.45 CBDA: 1.06 ± 0.3
Pichini et al., 2020 [53] NR, OL, NP
Pilot
1 M
Oral Decoction
0.36 mg THC
1.6 mg THCA-A
0.42 mg CBD
4 mg CBDA
Blood Blood
Effects were not reported.
THC: 1.0 THC: 2.0
THCA-A: 72.4 THCA-A: 2.0
CBD: 1.5 CBD: 3.0
CBDA: 94.3 CBDA: 0.5
11-OH-THC: 1.2 11-OH-THC: 2.0
THC-COOH: 17.1 THC-COOH: 3.0
THC-COOH-GLUC: 40.2 THC-COOH-GLUC: 4.0
Oral fluid Oral fluid
THC: 0.2 THC: 0.5
THCA-A: 5.1 THCA-A: 0.5
CBD: 0.8 CBD: 0.5
CBDA: 145.2 CBDA: 0.5
Oral Oil
0.95 mg THC
1.5 mg THCA-A
0.86 mg CBD
2.8 mg CBDA
Blood Blood
THC: 0.5 THC: 2.0
THCA: 40.3 THCA-A: 2.0
CBD: 0.3 CBD: 2.0
CBDA: 32.4 CBDA: 1.5
11-OH-THC: 0.7 11-OH-THC: 2.0
THC-COOH: 4.3 THC-COOH: 2.0
THC-COOH-GLUC: 7.7 THC-COOH-GLUC: 3.0
Oral fluid Oral fluid
THC: 0.2 THC: 2
THCA: 1.0 THCA-A: 2
CBD: 0.6 CBD: 2
CBDA: 14.3 CBDA: 1
For abbreviations see Table 1.
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Table 3. Summary of studies included in this systematic review reporting the pharmacokinetic parameters of THC following tablet administration.
References Study Design Participants Route ofAdministration Formulation Dose
Cmax (ng/mL)
Mean ± SD, Median (Range) Tmax (h) Pharmacological Effects
Timpone et al.,
1997 [54]
R, OL
7 M/F
4 M/F
9 M/F
Patients with HIV wasting
syndrome
Oral Tablets(Marinol®) 2.5 mg THC Data from all 20 patients Data from all 20 patients
Subjective effects
Increase in VAS for hunger.
No differences in VAS for mood and nausea.
Oral Tablets(Marinol®)
2.5 mg THC
750 mg megestrol THC: 2.01 c (0.58–12.48) THC: 2.07 b (0.66–8.26)
Oral Tablets(Marinol®)
2.5 mg THC
250 mg megestrol 11-OH-THC: 4.61 c (0.52–37.5) 11-OH-THC: 2.07 b (0.49–8.00)
Klumpers et al.,
2011 [55]
R, DB, DD, P, C
4 M, 5 F
(in panel 1, 13 subjects)
Previous experience of
cannabis use (maximum 1 use
per week)
Sublingual Tablets(Namisol®) 5.0 mg THC 2.30 ± 1.01
e 1.24 ± 0.65 e
Subjective effects
Highest oral doses increased body sway and VAS for
calmness, external perception, and feeling high and
decreased VAS for alertness.
Vital effects
No significant differences in PD parameters between oral
and sublingual administration.
Significant increase in HR.
Oral Tablets(Namisol®) 5.0 mg THC 2.92 ± 1.49
e 0.93 ± 0.68 e
Oral Tablets(Namisol®) 6.5 mg THC 4.43 ± 1.86
e 0.66 ± 0.13 e
Oral Tablets(Namisol®) 8.0 mg THC 4.69 ± 2.91
e 0.73 ± 0.19 e
Oral Tablets(placebo)
Ahmed et al.,
2014 [56]
R, DB, P, DD, C 6 M, 5 F
Oral Tablets(Namisol®) 3 mg THC 1.42 (0.53–3.48) 0.92 (0.67–0.92) Subjective effects
No subjective effects (exc. 4 subjects “felt high”)
Vital effects
Mild PD effects.
No changes in SBP, DBP, and HR.
Psychomotor performance
No changes in psychomotor performance.
Oral Tablets(Namisol®) 5 mg THC 3.15 (1.54–6.95) 0.92 (0.67–0.92)
Oral Tablets(Namisol®) 6.5 mg THC 4.57 (2.11–8.65) 0.67 (0.67–0.92)
Oral Tablets(placebo)
De Vries et al.,
2016 [57]
R, DB, P, C
15 M, 9 F
Patients diagnosed with
chronic pancreatitis
No cannabis use in previous
year
Oral
Tablets
(Namisol®)
8 mg THC THC: 4.01 ± 3.39 2.05 + 1.47 Subjective effects No differences in subjective effects
(alertness, mood, calmness, or balance) between treatments.
Anxiousness, somnolence, dry mouth, dizziness, and
euphoric mood after THC administration. Vital effects No
changes in SBP and DBP. THC induced an increase in HR
compared to diazepam.
11-OH-THC: 4.38 ± 1.50 2.26 ± 1.29
Oral Tablet (activeplacebo)
5 mg diazepam to
non-opioid group/10
mg diazepam to
opioid group
For abbreviations see Table 1.
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Table 4. Summary of studies included in this systematic review reporting the pharmacokinetic parameters for THC following baked goods’ administration.
References Study Design Participants Route ofAdministration Formulation Dose
Cmax (ng/mL)
Mean ± SD, Median (Range) Tmax (h) Pharmacological Effects
Ohlsson et al.,
1980 [58]
R, OL, NP, C
11 M
Previous experience of
cannabis use (from infrequent
to frequent use)
Smoked Cigarette
19 mg THC (ad
libitum) (mean = 13.0
mg)
77, 33–118 a Subjective effects
Increase in high effect.
Vital effects
Increase in HR.
Conjunctival reddening
Oral Chocolate cookie 20 mg THC 4.4–11 a 1–1.5
Intravenous Normal saline ethanolicsolution 5 mg THC 219, 161–316
a
Watchel et al.,
2002 [59]
DB, P, C
7 M, 5 F
7 M, 6 F
Previous experience of
cannabis use
Oral Cannabis (plant) brownie 8.4 mg THC ≈ 4.1 b, d 3 b, d Subjective effects
Both drugs increased VAS
sedation and ARCI PCAG scale
scores, and decreased the ARCI
BG scale scores at higher doses.
Cannabis in high doses
increased VAS for sedation,
drowsiness, and tiredness.
THC in high doses increased
ARCI A scale scores, MBG
(euphoria), and LSD
(dysphoria). Vital effects No
effects on physiological or
behavioral measures.
Oral Cannabis (plant) brownie 16.9 mg THC ≈ 6.8 b, d 2.5 b, d
Oral THC (synthetic) brownie 8.4 mg THC ≈ 4.8 b, d 2.5 b, d
Oral THC (synthetic) brownie 16.9 mg THC ≈ 9 b, d 2.5 b, d
Smoked Cannabis (plant) cigarette 8.4 mg THC ≈ 36 b, d 0.08 b, d
Smoked Cannabis (plant) cigarette 16.9 mg THC ≈ 60 b, d 0.08 b, d
Smoked THC (synthetic) cigarette 8.4 mg THC ≈ 31 b, d 0.08 b, d
Smoked THC (synthetic) cigarette 16.9 mg THC ≈ 56 b, d 0.08 b, d
Oral Brownie (placebo)
Smoked Cigarette (placebo)
Newmeyer
et al., 2016 [60]
R, DB, P, DD, C 9 M, 2 F frequent smokers
6 M, 3 F occasional smokers
Oral Brownie
50.6 mg THC (ad
libitum)
1.5 mg CBD
3.3 mg CBN
Frequent smokers Frequent smokers
Effects were not described.
THC: 15.3, 14.3 (1.4–32.4) THC: 2.5, 2.5 (1.5–3.5)
11-OH-THC: 7.3, 6.2 (0.9–13.7) 11-OH-THC: 2.3, 2.5 (1.5–3.5)
THC-COOH: 36.4, 35.3 (4.3–99.4) THC-COOH: 2.7, 2.5 (2.5–3.5)
THCV-COOH: 2.1, 2.0 (1.1–3.4) THCV-COOH: 3.0, 3.0 (2.5–3.5)
THC-COOH-gluc: 53.0, 57.1
(10.3–75.7) THCOOH-gluc: 3.4, 3.5 (1.5–5.0)
Occasional smokers Occasional smokers
THC: 10.3, 10.1 (3.6–22.5) THC: 2.3, 2.5 (1.5–3.5)
11-OH-THC: 5.5, 5.1 (2.4–11.0) 11-OH-THC: 2.4, 2.5 (1.5–3.5)
THC-COOH: 39.8, 37.8 (12.5–70.4) THC-COOH: 2.9, 3.5 (1.5–3.5)
THCV-COOH: 1.9, 1.9 (1.1–2.7) THCV-COOH: 2.6, 2.5 (1.5–3.5)
THC-COOH-gluc: 124, 124 (70.9–178) THC-COOH-gluc: 4.7, 5.0 (3.5–5.0)
Smoked Cigarette
50.6 mg THC (ad
libitum)
1.5 mg CBD
3.3 mg CBN
Frequent smokers Frequent smokers
THC: 151, 114 (51.6–467) THC: 0.12, 0.13 (0.00–0.17)
11-OH-THC: 9.0, 6.5 (1.9–30.2) 11-OH-THC: 0.21, 0.20 (0.10–0.50)
THC-COOH: 23.5, 20.0 (5.7–64.9) THC-COOH: 0.28, 0.25 (0.00–0.50)
THCV-COOH: 2.4, 2.4 (1.8–3.1) THCV-COOH: 0.22, 0.23 (0.17–0.25)
THC-COOH-gluc: 25.8, 14.1 (5.0–70.7) THC-COOH-gluc: 1.1, 0.5 (0.0–3.5)
Occasional smokers Occasional smokers
THC: 51.6, 44.4 (1.3–174) THC: 0.11, 0.10 (0.07–0.17)
11-OH-THC: 2.8, 1.9 (0.5–8.7) 11-OH-THC: 0.22, 0.19 (0.10–0.50)
THC-COOH: 8.4, 7.4 (0.7–17.5) THC-COOH: 0.31, 0.25 (0.10–0.50)
THCV-COOH: - THCVCOOH: -
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Table 4. Cont.
References Study Design Participants Route ofAdministration Formulation Dose
Cmax (ng/mL)
Mean ± SD, Median (Range) Tmax (h) Pharmacological Effects
Inhaled Vaporizer Volcano
50.6 mg THC (ad
libitum)
1.5 mg CBD
3.3 mg CBN
Frequent smokers Frequent smokers
THC: 84.7, 83.1 (23.5–169) THC: 0.09, 0.10 (0.03–0.17)
11-OH-THC: 4.8, 4.2 (1.6–9.8) 11-OH-THC: 0.19, 0.17 (0.10–0.50)
THC-COOH: 13.0, 12.5 (4.1–31.3) THC-COOH: 0.25, 0.25 (0.13–0.50)
THCV-COOH: 1.7, 1.8 (1.2–2.1) THCV-COOH: 0.52, 0.21 (0.17–1.5)
THC-COOH-gluc: 10.9, 10.6 (0.8–23.8) THC-COOH-gluc: 1.8, 1.5 (0.03–3.5)
Occasional smokers Occasional smokers
THC: 47.8, 34.8 (5.2–137) THC: 0.11, 0.10 (0.03–0.17)
11-OH-THC: 2.0, 1.6 (0.7–3.5) 11-OH-THC: 0.15, 0.15 (0.10–0.20)
THC-COOH: 7.2, 5.3 (1.4–15.9) THC-COOH: 0.33, 0.25 (0.20–0.50)
THCV-COOH: - THCV-COOH: -
THC-COOH-gluc: 15.1, 16.1 (5.3–23.7) THC-COOH-gluc: 1.9, 2.5 (0.5–2.5)
Oral Brownie (placebo)
Smoked Cigarette (placebo)
Inhaled Vaporizer (placebo)
Newmeyer
et al., 2017 [61]
Optional dosing
session under the
same clinical protocol
followed in
Newmeyer et al., 2016
9 M frequent smokers
5 M, 2 F occasional smokers Oral Brownie
50.6 mg THC
1.5 mg CBD
3.3 mg CBN
(ad libitum)
Frequent smokers Frequent smokers
Effects were not assessed.
Blood Blood
THC: 16.2, 12.8 (5.3–34.6) THC: 2.5, 3.5 (1.0–3.5)
11-OH-THC: 58.4, 50.0 (27.8–152) 11-OH-THC: 2.8, 3.5 (1.0–3.5)
THC-COOH: 58.4, 50.0 (27.8–152) THC-COOH: 3.3, 3.5 (1.5–3.5)
THCV-COOH: 1.9, 1.6 (1.1–3.9) THCV-COOH: 3.1, 3.5 (1.5–3.5)
THC-COOH-gluc: 68.5, 61.2 (50.6–110) THC-COOH-gluc: 4.8, 5.0 (3.5–8.0)
Oral fluid Oral fluid
THC: 573, 464 (39.3–2111) THC: 0.33
11-OH-THC: 0.6, 0.7 (0.2–1.2) 11-OH-THC: 0.40, 0.33 (0.33–1.0)
THC-COOH: 285, 186 (123–849) THC-COOH: 12, 5 (3.5–48)
THCV-COOH: 7.4, 6.8 (1.3–19.4) THCV-COOH: 0.33
Occasional smokers Occasional smokers
Blood Blood
THC: 8.2, 8.6 (3.2–14.3) THC: 2.2, 1.5 (1.0–5.0)
11-OH-THC: 5.6, 5.2 (4.1–8.6) 11-OH-THC: 2.6, 3.5 (1.5–3.5)
THC-COOH: 39.7, 38.2 (26.5–61.2) THC-COOH: 3.2, 3.5 (1.5–3.5)
THCV-COOH: 1.6, 1.6 (1.1–2.1) THCVCOOH: 2.3, 1.5 (1.0–3.5)
THC-COOH-gluc: 86.2, 73.5 (43.1–183) THCOOH-gluc: 4.6, 5.0 (3.5–6.0)
Oral fluid Oral fluid
THC: 362, 392 (115–696) THC: 0.33
11-OH-THC: 0.4, 0.4 (0.3–0.6) 11-OH-THC: 0.60, 0.33 (0.33–1.5)
THC-COOH: 315, 191 (27.9–1263) THC-COOH: 10, 10 (0.33–20)
THCV-COOH: 5.4, 4.7 (1.6–10.6) THCV-COOH: 0.33
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Table 4. Cont.
References Study Design Participants Route ofAdministration Formulation Dose
Cmax (ng/mL)
Mean ± SD, Median (Range) Tmax (h) Pharmacological Effects
Vandrey et al.,
2017 [62]
R, DB, NP
9 M, 9 F
Previous experience of
cannabis use but not exposed
within the previous 3 months
Oral Brownie 10 mg THC
Blood Blood
Subjective effects
Significant subjective and
cognitive drug effects at the 25
and 50 mg doses.
Vital effects
Significant PD effects.
Psychomotor performance
Significant effects on
psychomotor performance at
the 25 and 50 mg doses.
THC: 1.0 (0–3) THC: 0.9 (0–2)
11-OH-THC: 1.0 (0–2) 11-OH-THC: 1.3 (0–3)
THC-COOH: 7.2 (5–14) THC-COOH: 3.2 (2–4)
Oral fluid Oral fluid
THC: 191.5 (47–412) THC: 0.2 (0.2–0.5)
THC-COOH: 0.051 (0–0.231) THC-COOH: 1.0 (0–3)
Oral Brownie 25 mg THC
Blood Blood
THC: 3.5 (3.0–4) THC: 2.6 (1.0–4)
11-OH-THC: 3.3 (2–5) 11-OH-THC: 3.0 (1.5–4)
THC-COOH: 21.3 (12–39) THC-COOH: 3.3 (1.5–6)
Oral fluid Oral fluid
THC: 477.5 (70–1128) THC: 0.2 (0.2–0.5)
THC-COOH: 0.140 (0.023–0.251) THC-COOH: 9.8 (3–30)
Oral Brownie 50 mg THC
Blood Blood
THC: 3.3 (1.0–5) THC: 2.3 (1.0–6)
11-OH-THC: 3.2 (2–4) 11-OH-THC: 1.8 (1–3)
THC-COOH: 29.3 (16–44) THC-COOH: 3.3 (1.5–6)
Oral fluid Oral fluid
THC: 597.5 (350–1010) THC: 0.2 (0.2–0.5)
THC-COOH: 0.314 (0–0.822) THC-COOH: 17.4 (0–54)
For abbreviations, see Table 1.
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Overall, these studies showed remarkable heterogeneity in their designs and the conditions
under which they were conducted. Most studies included small sample sizes, and not all of them
included subjects of both genders. There were also discrepancies in the cannabis experience levels
of the participants and their health statuses, since patients with diverse pathologies (HIV, chronic
pancreatitis, and medication overuse-related headaches) were targeted in several studies. Most of the
studies involved THC administration alone, although THC was administered in combination with
CBD in eight studies. Apart from other cannabinoids, THC was also administered combined with
other drugs, such as megestrol acetate, naltrexone, and morphine.
Some studies included evaluations of physiological and/or subjective effects after administration
of the different preparations. THC/cannabis was found to produce its prototypical effects, presenting
mild changes in blood pressure or heart rate, increases in scores of high and positive effects, increased
feelings of sedation/drowsiness, and mild impairment of psychomotor performance. See Tables 1–4 for
detailed descriptions of these effects in different studies according to various formulations.
3.1. Capsules
Cannabis capsules usually contain cannabis or synthetic THC (dronabinol) in oil due to its higher
bioavailability (see also the oil section). In our search, 14 studies investigated cannabis/THC/dronabinol
administration dissolved in oil capsules, thus representing the most frequently studied dosage form
among all oral formulations [37–50].
The dose of THC contained in the oil capsules in single-dose studies ranged from 5 to 90 mg.
The Cmax in plasma ranged from 0.42 to 29.9 ng/mL, and the Tmax ranged from 0.78 to 4 h.
PK differences were examined after administering the same cannabinoid doses (10.8 mg of THC and
10.0 mg of CBD) using THC and CBD-piperine-pro-nanolipospheres (THC-CBD-PNL) capsules, which
are an alternative to oil capsules, and an oromucosal spray (Sativex®). THC-CBD-PNL produced
a three-fold increase in Cmax compared to Sativex® (5.4 and 1.8 ng/mL of THC, respectively) and
a faster absorption of cannabinoids (a Tmax of 1 h and 2 h for THC and of 1 h and 2 h for CBD,
respectively) [51]. See Table 1 for the specific results.
The correlation between the administered dose and Cmax resulted in a Pearson’s r value of
0.9271 and a coefficient of determination (R2) of 0.8596 (Table 5, Figure 2). The THC Cmax increased
proportionally by increasing the doses of THC.
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Figure 2. The correlation between the dose of administered THC and the maximum concentration
(Cmax) of THC in plasma following administration of capsules (a), decoctions (b), oils (c), tablets (d),
and baked goods (e).
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Table 5. Correlation between doses of THC and the maximum plasma concentration (Cmax) values in
each formulation group.
Capsules Decoction Oil Tablets Baked Goods
Pearson’s r 0.9271 0.9997 0.3806 0.9178 0.6365
95% confidence interval 0.8492 to 0.9656 0.9851 to 1.000 −0.9154 to 0.9824 0.6032 to 0.9853 0.09838 to 0.8866
p value (two-tailed) <0.0001 0,0003 0.6194 0.0013 0.0261
R2 0.8596 0.9994 0.1448 0.8423 0.4051
3.2. Oil
In previous studies, oil extracts showed greater cannabinoid extraction efficiency than water [31].
In addition to a higher bioavailability, oil formulations are considered suitable solvents to compose
a THC therapeutic preparation. In this section, we only considered the administration of oil-based
cannabis (see above for capsules containing oil). Only three studies were found in which oil was
directly ingested [43,52,53]. Among these three studies, only two reported single-dose administrations.
In one of these studies, subjects received 2.2 mg of THC and 2.3 mg of ∆-9-tetrahydrocannabinolic
acid A (THCA-A), obtaining a Cmax of 3.29 and 65.36 ng/mL, respectively, and a Tmax of 1.28 and
1.33 h in plasma [52]. The other study reported data on one healthy individual treated with a cannabis
decoction and oil (pilot study). The subject received 0.45 mL of oil containing 0.95 mg of THC, 1.5 mg
of THCA-A, 0.86 mg of CBD, and 2.8 mg of cannabidiolic acid (CBDA). The THC and THCA-A Cmax
in serum following oil administration were 0.5 and 40.3 ng/mL, respectively, with a Tmax of 2.0 h for
both cannabinoids [53]. See Table 2 for the specific results.
In this formulation, among the three studies included, the administered dose of THC showed a
weak and not significant correlation with the Cmax (Pearson’s r = 0.3806, p value = 0.6194) (Table 5,
Figure 2).
3.3. Decoctions
Decoctions are also called “tea” in several articles. Only three studies examining cannabinoid
PK after cannabis decoction administration were retrieved, including one study with a milk
decoction [41,52,53]. For the milk decoction, two doses were selected—a low THC dose of 16.5 mg
and a high dose of 45.7 mg, achieving a Cmax of 3.8 and 8.4 ng/mL, respectively, and a Tmax of 1 h
in plasma for both doses [41]. In another study, cannabis was boiled in water, obtaining a decoction
composed of 1.85 mg THC and 2.22 mg of THCA-A. After consumption of this decoction, the THC
reached a mean Cmax of 1.38 ng/mL with a Tmax of 1.28 h, whereas THCA-A reached a mean Cmax
of 48.92 ng/mL in plasma with a Tmax of 1.22 h [52]. In the pilot study mentioned in the Oil section,
the subject received 100 mL of a cannabis decoction containing 0.36 mg of THC, 1.6 mg of THCA-A,
0.42 mg of CBD, and 4 mg of CBDA. This oral dose resulted in a Cmax in the serum of 1.0 ng/mL of
THC and 72.4 ng/mL of THCA-A, with a Tmax of 2.0 h [53]. See Table 2 for the specific results.
Despite the few studies found, cannabis decoctions showed a significant strong correlation
between the dose of THC and peak plasma, with a Pearson’s r of 0.9997 and a correlation coefficient of
>0.99 (Table 5, Figure 2).
3.4. Tablets
Like oral capsules, tablets are also a stable dosage form that is considered practical for patient use.
Four studies were retrieved. Two of them focused on Namisol, a patented tablet formulation of pure
THC under investigation [54–57]. The PK data for THC doses varied from 2.5 to 8 mg, producing a
Cmax of 1.42–4.69 ng/mL and a Tmax of 0.66–2.07 h in plasma. See Table 3 for the specific results.
Tablet administration showed a strong correlation between the administered THC dose and the
Cmax, with a Pearson’s r of 0.9178 and a correlation coefficient of 0.8423 (Table 5, Figure 2).
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3.5. Baked Goods
Five studies evaluated the THC PK after brownie or cookie consumption [38,40,58,59,61]. The THC
doses in these edibles ranged from 8.4 to 50.6 mg, resulting in a Cmax of 1–16.2 ng/mL and a Tmax of
0.9–2.6 h in plasma. See Table 4 for specific results.
Brownies and cookies showed a weaker correlation between the dose of THC and the Cmax
compared to other formulations, resulting in a Pearson’s r of 0.6365 and a correlation coefficient of
0.4051 (Table 5, Figure 2).
4. Discussion
The purpose of this present review was to provide a general overview of the available THC
PK data after oral administration. In our literature review, we found that human PK studies
studying the administration of THC in oral forms were scarce, despite their increasing popularity.
Most of these studies focused on pharmaceutical forms, such as capsules and tablets. Despite being
recommended formulations for the therapeutic use of cannabis in some countries, there were few
data on the cannabinoid PK after the ingestion of cannabis oils or decoctions. The only complete,
published study comparing these two formulations in patients with medication overuse-related
headaches found high variability in the cannabinoid content of these formulations and in the THC
recovery after administration. Each preparation showed differences in cannabinoid and metabolite
absorption. For instance, cannabis decoctions offered a higher bioavailability of CBDA, while cannabis
oil provided a higher bioavailability of THC and its metabolites, 11-hydroxy-∆-9-tetrahidrocannabinol
(11-OH-THC) and 11-nor-9-carboxy-∆-9-tetrahidrocannabinol (THC-COOH) [52]. Contrary to these
results, a published pilot study that also compared oil and decoction formulations obtained higher
CBDA, THC, 11-OH-THC, and THC-COOH Cmax values after the administration of decoctions [53].
However, this pilot only presented data from one subject; results from a larger number of participants
would likely strengthen comparisons between these two studies.
In our review, we found three studies that compared the oral administration of THC with that of
smoking/inhalation, the most common route of administration. In Ohlsson et al. [58], subjects smoked
19.0 mg of THC (ad libitum, with a mean of 13.0 mg of THC) and took an oral dose of 20 mg of THC
via a chocolate cookie. Despite being administered in a similar dose, the Cmax obtained after smoking
(33–118 ng/mL) was significantly higher than the oral administration (4.4–11 ng/mL). These results
showed the low systemic bioavailability of oral THC, which is about a third of that from smoked
THC. Similarly, in Watchel et al. [59], the same doses of synthetic or plant-derived THC were orally
administered and smoked, but the Cmax obtained was six times higher after smoking than after oral
administration. As expected, the oral form achieved a delayed Tmax since absorption is slower when
cannabinoids are ingested. Newmeyer et al. [60] reported minimal differences between smoked and
vaporized cannabis administration, observing similar delivery. However, the THC Cmax after oral
administration (brownie) was significantly lower than that of other routes, in addition to having a
delayed Tmax, which agrees with previous observations.
For capsules, a wider range of doses was evaluated compared to other forms. Lile et al.
administered the highest dose of THC (90 mg) out of all the studies and consequently reported the
highest THC Cmax mean value obtained after administration (approx. 53 ng/mL) [49].
Oral THC doses were moderately to highly correlated (Pearson’s r = 0.6365–0.9997 and
R2 = 0.4051–0.9994), with peak plasma concentrations of THC found in capsules, decoctions, tablets,
and baked goods formulations (Table 5, Figure 2). This correlation was stronger for capsules, decoctions,
and oil compared to baked goods, which appeared to have higher variability in the peak plasma value
obtained after certain THC doses. Interestingly, for oil, the correlation was not significant, thereby
suggesting a more irregular absorption profile (Figure 2). Since THC is a highly lipophilic molecule,
it is expected that its absorption will increase in oil-based formulations. More studies on cannabis oil
PK could determine whether this lack of linear correlation, as proven in other formulations, persists
due to a high variability in the THC absorption of cannabis oil.
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The management of dosing is critical for the treatment of patients, as there is a balance between
the desired medical effects of THC and the prevention of adverse effects. Analyzing and understanding
the PK of oral THC preparations is essential for the selection of optimal formulations, given their high
variability. For instance, dronabinol in a solution exhibits lower intra-individual variability and a faster
onset of detectable concentrations compared to capsule formulations [24,50].
We found that most studies on oral PK are focused on synthetic forms and analogues of THC,
without considering the other cannabinoids usually present in plant-derived products, thus disregarding
their possible therapeutic contributions. Moreover, the presence of CBD and other cannabinoids
contained in oral cannabis preparations may be involved in alterations of THC PK properties [14].
In 2017, a review examining the PK and pharmacodynamics (PD) of oral cannabinoids for the
treatment of chemotherapy-induced nausea and vomiting emphasized the high variability in the
PK/PD profiles of capsules [63] and how they differ from other routes, such as smoking and intravenous
delivery. The authors remarked on the efficacy of oral cannabinoids in the management of nausea
and vomiting, which is similar, or even superior, to conventional antiemetic drugs. Interestingly,
participants showed a preference for cannabis-based medicines over conventional medicines in trials
where the two options were compared.
Similarly, a systematic review was recently conducted on CBD PK in humans, regardless of
the administration route. Contrary to THC, CBD PK has been more thoroughly studied after oral
and oromucosal administration (e.g., oral capsules and oromucosal sprays) than other routes of
administration, such as smoking or vaporization. The most commonly studied form of administration
was oromucosal spray, which contained CBD in combination with THC. Indeed, the administration
of CBD alone in cannabinoid PK studies appeared less frequently than THC alone. Thus, like THC,
the authors concluded that the limited available data presented some discrepancies in the PK of
CBD [64].
The main limitation of the present systematic review is its use of only the PubMed database,
the inclusion of only publications in English, and the exclusion of studies on the oromucosal sprays
nabilone and those that administer only CBD.
5. Conclusions
In conclusion, oral THC has a highly variable PK profile, which differs between formulations,
with seemingly higher variability in baked goods and oil forms. Considering the rapidly changing
landscape of medical cannabis laws, there is an evident need for solid PK data after oral administration,
especially in dosage forms other than capsules. Particularly, there is a lack of PK data on decoctions
(tea) and oils, which are recommended methods of ingestion for medical use. Insufficient studies may
lead to future failures of cannabis as a therapeutic compound if its therapeutic window is not defined.
The present review collects all published data on the oral administration of THC and cannabis in
humans. Our results show high variability between oral formulations but a positive dose–concentration
relationship for THC in most preparations.
Further investigations are required to provide more data on cannabinoid PK in the oral
administration of THC, as well as other cannabinoids, to increase the accuracy when defining a
therapeutic dosage for every patient.
Author Contributions: Conceptualization, L.P., A.P.P.-A., E.P., C.P.-M., A.S., M.T., F.P.B., and M.F.; methodology,
L.P., A.P.P.-A., M.T., and M.F.; data curation, L.P., A.P.P.-A., S.M., O.H., A.S., and M.F.; writing—original draft
preparation, L.P., A.P.P.-A., and M.F.; writing—review and editing, all authors. All authors have read and agreed
to the published version of the manuscript.
Funding: The investigation was partially carried out with the funding of grants from the Instituto de Salud Carlos
III (ISCIII, Fondo Investigación sanitaria (FIS)-Fondo Europeo de Desarrollo Regional (FEDER), FIS PI14/00715 and
FIS PI17/01962, predoctoral PFIS FI18/00179 (L. Poyatos), ISCIII-Red de Trastornos Adictivos RTA RD16/0017/0003
and RD16/0017/0010), Ministerio de Sanidad, Política Social e Igualdad (Plan Nacional Sobre Drogas-PNSD,
2015I054 and 2019I010), and Agencia de Gestión de Ayudas Universitarias y de Investigación (AGAUR) Gencat
Suport Grups Recerca (2017 SGR 316 and 2017 SGR 530).
Medicina 2020, 56, 309 18 of 21
Conflicts of Interest: The authors declare no conflict of interest.
References
1. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2019. Available online:
https://wdr.unodc.org/wdr2019/index.html. (accessed on 5 April 2020).
2. Morales, P.; Hurst, D.P.; Reggio, P.H. Molecular Targets of the Phytocannabinoids: A Complex Picture.
Prog. Chem. Org. Nat. Prod. 2017, 103, 103–131. [PubMed]
3. ElSohly, M.A.; Radwan, M.M.; Gul, W.; Chandra, S.; Galal, A. Phytochemistry of Cannabis sativa L. Prog. Chem.
Org. Nat. Prod. 2017, 103, 1–36. [PubMed]
4. Kaur, R.; Ambwani, S.R.; Singh, S. Endocannabinoid System: A Multi-Facet Therapeutic Target. Curr. Clin.
Pharmacol. 2016, 11, 110–117. [CrossRef]
5. Maccarrone, M.; Maldonado, R.; Casas, M.; Henze, T.; Centonze, D. Cannabinoids therapeutic use: What is
our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?
Expert Rev. Clin. Pharmacol. 2017, 10, 443–455. [CrossRef]
6. Andre, C.M.; Hausman, J.F.; Guerriero, G. Cannabis sativa: The Plant of the Thousand and One Molecules.
Front. Plant. Sci. 2016, 7, 19. [CrossRef] [PubMed]
7. Pisanti, S.; Malfitano, A.M.; Ciaglia, E.; Lamberti, A.; Ranieri, R.; Cuomo, G.; Abate, M.; Faggiana, G.;
Proto, M.C.; Fiore, D.; et al. Cannabidiol: State of the art and new challenges for therapeutic applications.
Pharmacol. Ther. 2017, 175, 133–150. [CrossRef]
8. Mannucci, C.; Navarra, M.; Calapai, F.; Spagnolo, E.V.; Busardò, F.P.; Cas, R.D.; Ippolito, F.M.; Calapai, G.
Neurological Aspects of Medical Use of Cannabidiol. CNS Neurol. Disord. Drug Targets 2017, 16, 541–553.
[CrossRef]
9. Laprairie, R.B.; Bagher, A.M.; Kelly, M.E.M.; Denovan-Wright, E.M. Cannabidiol Is a Negative Allosteric
Modulator of the Cannabinoid CB1 Receptor. Br. J. Pharmacol. 2015, 172, 4790–4805. [CrossRef]
10. Mueller, J.K.; Reuter, A.R.; Lange, B.; Schaefer, A.; Hanke, F.; Pahlisch, F.; Schaefer, C.; Schmidt, A.-M.;
Woelfl, T.; Enning, F.; et al. Effects and interaction of delta-9-tetrahydrocannabidiol and cannabidiol on
psychopathology, neurocognition, and endocannabinoids in serum of healthy volunteers: Influence on
psychopathology. Neuropsychopharmacology 2016, 41, S589.
11. Morgan, C.J.A.; Freeman, T.P.; Hindocha, C.; Schafer, G.; Gardner, C.; Curran, H.V. Individual and combined
effects of acute delta-9tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory
function. Transl. Psychiatry 2018, 8, 181. [CrossRef]
12. Hindley, G.; Beck, K.; Borgan, F.; Ginestet, C.E.; McCutcheon, R.; Kleinloog, D.; Ganesh, S.; Radhakrishnan, R.;
D'Souza, D.C.; Howes, O.D. Psychiatric symptoms caused by cannabis constituents: A systematic review
and meta-analysis. Lancet Psychiatry 2020, 7, 344–353. [CrossRef]
13. Arkell, T.R.; Lintzeris, N.; Kevin, R.C.; Ramaekers, J.G.; Vandrey, R.; Irwin, C.; Haber, P.S.; McGregor, I.S.
Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced
impairment of driving and cognition. Psychopharmacology 2019, 236, 2713–2724. [CrossRef] [PubMed]
14. Papaseit, E.; Pérez-Mañá, C.; Pérez-Acevedo, A.P.; Hladun, O.; Torres-Moreno, M.C.; Muga, R.; Torrens, M.;
Farré, M. Cannabinoids: From pot to lab. Int. J. Med. Sci. 2018, 6, 1286–1295. [CrossRef] [PubMed]
15. Hazekamp, A.; Heerdink, E.R. The prevalence and incidence of medicinal cannabis on prescription in The
Netherlands. Eur. J. Clin. Pharmacol. 2013, 69, 1575–1580. [CrossRef]
16. de Hoop, B.; Heerdink, E.R.; Hazekamp, A. Medicinal Cannabis on Prescription in The Netherlands: Statistics
for 2003–2016. Cannabis Cannabinoid Res. 2018, 3, 54–55. [CrossRef]
17. Shiplo, S.; Asbridge, M.; Leatherdale, S.T.; Hammond, D. Medical cannabis use in Canada: Vapourization
and modes of delivery. Harm Reduct. J. 2016, 13, 30. [CrossRef]
18. Boehnke, K.F.; Scott, J.R.; Litinas, E.; Sisley, S.; Clauw, D.J.; Goesling, J.; Williams, D.A. Cannabis Use
Preferences and Decision-making Among a Cross-sectional Cohort of Medical Cannabis Patients with
Chronic Pain. J. Pain 2019, 20, 1362–1372. [CrossRef]
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